Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if Vidaza (azacitidine) when given to
patients with CML after an donor stem cell transplant will increase the likelihood of
achieving a complete remission of CML.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Celgene Corporation National Cancer Institute (NCI)